New shot could slash bad cholesterol in High-Risk asian patients

NCT ID NCT04765657

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tests a drug called inclisiran in about 345 Asian patients with high cholesterol and heart disease or high risk for it. The drug is given as an injection alongside standard statin therapy. The main goal is to see if it safely lowers 'bad' LDL cholesterol more than a placebo over about 11 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Lanzhou, Gansu, 730030, China
Novartis Investigative Site

Foshan, Guangdong, 528000, China
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site

Baotou, Inner Mongolia, 014040, China
Novartis Investigative Site

Hohhot, Inner Mongolia, 010017, China
Novartis Investigative Site

Nanjing, Jiangsu, 210008, China
Novartis Investigative Site

Nanjing, Jiangsu, 211166, China
Novartis Investigative Site

Nantong, Jiangsu, 226000, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Xuzhou, Jiangsu, 221003, China
Novartis Investigative Site

Changchun, Jilin, 130000, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Jinan, Shandong, 250013, China
Novartis Investigative Site

Jinshan, Shanghai Municipality, 201508, China
Novartis Investigative Site

Taiyuan, Shanxi, 030002, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Tianjin, Tianjin Municipality, 300121, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310014, China
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Beijing, 100039, China
Novartis Investigative Site

Beijing, 100050, China
Novartis Investigative Site

Beijing, 100191, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Shanghai, 200040, China
Novartis Investigative Site

Shanghai, 200080, China
Novartis Investigative Site

Shanghai, 200120, China
Novartis Investigative Site

Tianjin, 300052, China
Novartis Investigative Site

Tianjin, 300140, China
Novartis Investigative Site

Xiamen, 361004, China
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 169609, Singapore
Novartis Investigative Site

Wŏnju, Gangwon-do, 26427, South Korea
Novartis Investigative Site

Incheon, Korea, 405 760, South Korea
Novartis Investigative Site

Seoul, Korea, 02841, South Korea
Novartis Investigative Site

Seoul, Korea, 03080, South Korea
Novartis Investigative Site

Seoul, Seoul, 06351, South Korea
Novartis Investigative Site

Seoul, South Korea, 110-746, South Korea
Novartis Investigative Site

Gwangju, 61469, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Kaohsiung City, 80756, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Taipei, 11220, Taiwan

Conditions

Explore the condition pages connected to this study.

HYPERCHOLESTEROLEMIA